Benchmark against your competition
Understand how AI crawlers access your site
See where AI gets info about you
Track the queries mentioning your brand
Own your AI narrative
Add GEO to your service offerings
Get recommended in shopping queries
Monitor AI mentions at scale
Madrigal Pharmaceuticals
What AI says about Madrigal Pharmaceuticals
Madrigal Pharmaceuticals is dedicated to developing novel therapeutics for MASH, a serious liver disease with significant unmet medical needs. The company has achieved the first FDA approval for a treatment in this area, aiming to halt or reverse liver scarring and improve patient outcomes.
Is this your brand?
Claim this profile to keep your information accurate and add what's missing.
Products & Services
Resmetirom
A thyroid hormone receptor-β (THR-β) agonist developed as a treatment for metabolic dysfunction-associated steatohepatitis (MASH).
Common Questions
What is MASH?
MASH, or metabolic dysfunction-associated steatohepatitis, is a serious liver disease characterized by inflammation and scarring of the liver due to fat accumulation.
What is the goal of Madrigal Pharmaceuticals?
Madrigal aims to develop therapies that halt or reverse liver scarring and resolve MASH before patients experience severe complications.
Where is Madrigal Pharmaceuticals located?
Madrigal Pharmaceuticals is based in Conshohocken, Pennsylvania, with operations in the United States and Europe.
When was Madrigal Pharmaceuticals founded?
Madrigal Pharmaceuticals was founded in 2011.
What is Resmetirom?
Resmetirom is a novel therapeutic developed by Madrigal Pharmaceuticals for the treatment of MASH, which has received FDA approval.